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EDITORIAL
Welcome to our final publication of 2017. This edition is bountiful 
and it extends our understanding of diabetes and obesity more 
completely. It is also extensive and involves research undertaken 
in Iran, Nigeria, Guinea, the Western Cape, and Johannesburg. As 
such, it highlights many of the “on-the-ground” challenges the 
developing world, including South Africa has to contend with. 
This edition also remains wide in its span and it alludes to many 
aspects of diabetes-obesity and includes basic science research, 
dietary application, public health challenges, quality of life and 
non-communicable disease, clinical outcomes and guideline 
updates. 
The use of probiotics to promote health is receiving increased 
attention and advocates of this therapy are also now focussed on 
their role in disease treatment. Asgharzadeh et al. investigated 
the role of probiotic therapy in reducing oxidative damage 
in the beta cell of a rat model. The practical investigation of 
indigenous diets is also presented and Olopade et al. identifies 
differing glycaemic indices within two sub-species of commonly 
consumed staple legume in Nigeria. The world is severely 
challenged by the diabetes epidemic, and a major component 
of this comprises of 50% of diabetic patients who do not even 
know they have diabetes. In this regard Baldo et al. confirms 
that this public health deficit is widely prevalent in Guinea. 
Obesity is associated with significant morbidity and its impact 
on quality of life is often overlooked. Tisane et al. report on a 
very unique cohort of obese and pregnant women (both with 
morbid- and super-obesity) and certainly provide evidence 
that, even from this psychological dimension, obesity should 
be classifiable as a formal disease. Apart from the “health care 
system” only able identify half the patients who have diabetes, 
we are also deficient in assuring that the 50% of the diagnosed 
patients achieve metabolic targets. Daya et al. indicates clearly, 
and disappointingly so, that 90% of diabetic patients attending 
a major hospital failed to attain LDL-cholesterol targets. Finally, 
a summarised flyer of the newly-revised SEMDSA guidelines 
provides near-ideal guidelines for therapy choices in our patients 
with uncomplicated, type2 diabetes. It is important to note 
that a “differentiated” guideline does exist for high-risk patients 
especially in the patients in whom secondary prevention from 
further cardiovascular events is indicated. 
From the editorial team of JEMDSA a happy and healthy New 
Year.
Jeffrey  Wing
